- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01386333
Safety Study of Intranasal Oxytocin in Frontotemporal Dementia (FTDOXY10EF)
November 1, 2013 updated by: Elizabeth Finger, Lawson Health Research Institute
A Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EF
Oxytocin is a hormone produced by the brain that appears to have important roles in social cognition and emotion in humans.
In a pilot study, the effects of a single dose of oxytocin on measures of emotion recognition and behaviour in patients with Frontotemporal Dementia were investigated.
The results from the pilot study suggested that oxytocin may be associated with a modest improvement in neuropsychiatric behaviours seen in patients with Frontotemporal Dementia.
To further examine the safety and tolerability of oxytocin in this disorder, the present study will examine the safety and tolerability of three different doses of intranasal oxytocin administered to patients with Frontotemporal Dementia twice daily for 1 week.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 4V2
- Cognitive Neurology and Alzheimer Research Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
28 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 30-80 years
- Meets "Neary criteria" for diagnosis of probable frontotemporal dementia
- Neuroimaging (CT, MRI or SPECT scan) supports diagnosis of frontotemporal dementia
- Provides written informed consent and has a caregiver or legally acceptable representative who provides written informed consent.
Exclusion Criteria:
- Has a history of a myocardial infarction within the last two years or congestive heart failure.
- Current uncontrolled hypertension
- Current bradycardia (rate < 50 beats per minute/bpm) or tachycardia (rate > 100 bpm)
- Current hyponatremia
- Current use of prostaglandin medications
- Females who are pregnant or breastfeeding
- Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug , whichever is longer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oxytocin 24IU
Oxytocin 24 IU administered intranasally twice daily for 1 week
|
Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
|
Experimental: Oxytocin 48 IU
48 IU of intranasal oxytocin administered twice daily for 1 week
|
Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
|
Experimental: 72 IU oxytocin
72 IU of intranasal oxytocin administered twice daily for 1 week
|
Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
|
Placebo Comparator: Saline nasal spray
|
Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: 2 week
|
Safety and Tolerability of 24 international units (IU), 48 IU and 72 IU of intranasal oxytocin administered twice daily for 1 week to patients with Frontotemporal Dementia as assessed by the number of participants with adverse events.
Adverse events will be assessed by a standardized questionnaire and serum sodium levels will be monitored.
|
2 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neuropsychiatric Inventory
Time Frame: 1 week
|
Behavioural ratings at baseline and 1 week of oxytocin treatment compared to 1 week of placebo treatment
|
1 week
|
Frontal Behavioural Inventory
Time Frame: 1 week
|
1 week
|
|
Clinicians Global Impression of Change
Time Frame: 1 week
|
1 week
|
|
Clinical Dementia Rating- Frontotemporal Lobar Degeneration
Time Frame: 1 week
|
1 week
|
|
Interpersonal Reactivity Index
Time Frame: 1 week
|
1 week
|
|
Multi-faceted Empathy Test
Time Frame: 1 week
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Elizabeth C Finger, MD, University of Western Ontario, Lawson Health Research Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (Actual)
October 1, 2013
Study Registration Dates
First Submitted
June 29, 2011
First Submitted That Met QC Criteria
June 30, 2011
First Posted (Estimate)
July 1, 2011
Study Record Updates
Last Update Posted (Estimate)
November 3, 2013
Last Update Submitted That Met QC Criteria
November 1, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Language Disorders
- Communication Disorders
- Speech Disorders
- Frontotemporal Lobar Degeneration
- Aphasia
- Dementia
- Frontotemporal Dementia
- Aphasia, Primary Progressive
- Pick Disease of the Brain
- Physiological Effects of Drugs
- Reproductive Control Agents
- Oxytocics
- Oxytocin
Other Study ID Numbers
- R-11-232
- 17783 (REB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frontotemporal Dementia
-
University of California, San FranciscoForest LaboratoriesCompletedSemantic Dementia | Frontal Lobe Dementia | Frontotemporal Lobe DementiaUnited States
-
Mayo ClinicRecruitingPrimary Progressive Aphasia | Behavioral Variant of Frontotemporal Dementia | Frontotemporal Dementia, Behavioral VariantUnited States
-
University of PennsylvaniaEnrolling by invitationFrontotemporal Degeneration | Frontotemporal Dementia | Frontotemporal Dementia, Behavioral Variant | FTDUnited States
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedTauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)United States
-
Massachusetts General HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Caregiver Stress Syndrome | Caregiver Burnout | Dementia, Mild | Dementia Moderate | Dementia Severe | Dementia FrontotemporalUnited States
-
BiogenCompletedFrontotemporal Dementia | Behavioral Variant Frontotemporal DementiaUnited States
-
Lawson Health Research InstituteRecruitingLewy Body Dementia (LBD) | Alzheimer Dementia (AD) | Dementia, FrontotemporalCanada
-
Vesper Biotechnologies ApSRecruitingDementia, FrontotemporalNetherlands
-
HealthPartners InstituteTerminatedFrontotemporal Dementia, Behavioral VariantUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); National Institute...CompletedFamilial Frontotemporal DementiaUnited States, Canada
Clinical Trials on oxytocin
-
Hillel Yaffe Medical CenterUnknownCervix; Insufficient Dilatation in LaborIsrael
-
University of NebraskaNational Institute of Mental Health (NIMH)Terminated
-
University of Electronic Science and Technology...Completed
-
GlaxoSmithKlineCompletedPostpartum HemorrhageUnited Kingdom
-
University of Electronic Science and Technology...Recruiting
-
GlaxoSmithKlineMonash University; InVentiv CliniqueTerminatedPostpartum HemorrhageAustralia, United Kingdom
-
University Hospital, ToulouseCompleted
-
OptiNose ASUniversity of OsloCompletedHealthy Male AdultsNorway
-
Washington University School of MedicineUniversity of MichiganRecruiting
-
University of NebraskaNot yet recruiting